JP2015534981A - Ｔｏｒキナーゼ阻害剤を用いた癌の治療 - Google Patents

Ｔｏｒキナーゼ阻害剤を用いた癌の治療 Download PDF

Info

Publication number
JP2015534981A
JP2015534981A JP2015537809A JP2015537809A JP2015534981A JP 2015534981 A JP2015534981 A JP 2015534981A JP 2015537809 A JP2015537809 A JP 2015537809A JP 2015537809 A JP2015537809 A JP 2015537809A JP 2015534981 A JP2015534981 A JP 2015534981A
Authority
JP
Japan
Prior art keywords
dihydropyrazino
pyrazin
methyl
pyridin
triazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015537809A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015534981A5 (enExample
Inventor
モーテンセン，デボラ
レイモン，ヘザー
ナーラ，ラマ，ケー．
ヘージ，クリステン，メー
ファルツ，キンバリー，エリザベス
ツジ，トシヤ
Original Assignee
シグナル ファーマシューティカルズ，エルエルシー
シグナル ファーマシューティカルズ，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シグナル ファーマシューティカルズ，エルエルシー, シグナル ファーマシューティカルズ，エルエルシー filed Critical シグナル ファーマシューティカルズ，エルエルシー
Publication of JP2015534981A publication Critical patent/JP2015534981A/ja
Publication of JP2015534981A5 publication Critical patent/JP2015534981A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015537809A 2012-10-18 2013-10-17 Ｔｏｒキナーゼ阻害剤を用いた癌の治療 Pending JP2015534981A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18
US61/715,510 2012-10-18
PCT/US2013/065363 WO2014062878A2 (en) 2012-10-18 2013-10-17 Treatment of cancer with tor kinase inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019012014A Division JP7162543B2 (ja) 2012-10-18 2019-01-28 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Publications (2)

Publication Number Publication Date
JP2015534981A true JP2015534981A (ja) 2015-12-07
JP2015534981A5 JP2015534981A5 (enExample) 2016-11-24

Family

ID=50023830

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015537809A Pending JP2015534981A (ja) 2012-10-18 2013-10-17 Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2019012014A Active JP7162543B2 (ja) 2012-10-18 2019-01-28 Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2020199055A Pending JP2021050213A (ja) 2012-10-18 2020-11-30 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019012014A Active JP7162543B2 (ja) 2012-10-18 2019-01-28 Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP2020199055A Pending JP2021050213A (ja) 2012-10-18 2020-11-30 Ｔｏｒキナーゼ阻害剤を用いた癌の治療

Country Status (19)

Country Link
US (1) US20140113904A1 (enExample)
EP (1) EP2908814B1 (enExample)
JP (3) JP2015534981A (enExample)
KR (2) KR102267927B1 (enExample)
CN (2) CN110721186A (enExample)
AU (1) AU2013202768B2 (enExample)
BR (1) BR112015008834A2 (enExample)
CA (1) CA2888609C (enExample)
EA (1) EA029164B1 (enExample)
ES (1) ES2777936T3 (enExample)
IL (1) IL238326B (enExample)
MX (1) MX368407B (enExample)
MY (1) MY176599A (enExample)
NI (1) NI201500055A (enExample)
PH (2) PH12020550858A1 (enExample)
SG (2) SG11201502999YA (enExample)
UA (1) UA117000C2 (enExample)
WO (1) WO2014062878A2 (enExample)
ZA (1) ZA201503105B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
JP6964343B2 (ja) * 2015-11-20 2021-11-10 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１阻害剤としてのプリノン
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506875A (ja) * 2008-10-27 2012-03-22 シグナル ファーマシューティカルズ，エルエルシー ｍＴＯＲ／ＰＩ３Ｋ／ＡＫＴ経路と関連した腫瘍学的徴候及び疾患のためのｍＴＯＲキナーゼ阻害剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159582C (zh) * 2001-12-08 2004-07-28 云南大学 一种人体全血或血清总前列腺特征性抗原值，总前列腺特征性抗原灰区值检测方法
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
US20070238745A1 (en) * 2006-04-07 2007-10-11 University Of South Florida PI3K-Akt Pathway Inhibitors
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
EP2457913B1 (en) * 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
JP2013508456A (ja) * 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ， エルエルシー ヘテロアリール化合物の合成方法および精製方法
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506875A (ja) * 2008-10-27 2012-03-22 シグナル ファーマシューティカルズ，エルエルシー ｍＴＯＲ／ＰＩ３Ｋ／ＡＫＴ経路と関連した腫瘍学的徴候及び疾患のためのｍＴＯＲキナーゼ阻害剤

Also Published As

Publication number Publication date
CA2888609C (en) 2020-12-01
CA2888609A1 (en) 2014-04-24
MX368407B (es) 2019-10-02
US20140113904A1 (en) 2014-04-24
WO2014062878A2 (en) 2014-04-24
PH12015500867B1 (en) 2015-06-22
CN110721186A (zh) 2020-01-24
WO2014062878A3 (en) 2014-06-26
EP2908814B1 (en) 2019-12-25
KR102267927B1 (ko) 2021-06-21
EP2908814A2 (en) 2015-08-26
JP7162543B2 (ja) 2022-10-28
KR102157914B1 (ko) 2020-09-18
NI201500055A (es) 2015-09-10
EA201590744A1 (ru) 2015-11-30
WO2014062878A9 (en) 2014-12-18
JP2019081771A (ja) 2019-05-30
PH12015500867A1 (en) 2015-06-22
ES2777936T3 (es) 2020-08-06
KR20150070319A (ko) 2015-06-24
SG10201810575WA (en) 2019-01-30
JP2021050213A (ja) 2021-04-01
AU2013202768B2 (en) 2015-11-05
ZA201503105B (en) 2016-11-30
SG11201502999YA (en) 2015-05-28
EA029164B1 (ru) 2018-02-28
PH12020550858A1 (en) 2023-02-20
BR112015008834A2 (pt) 2017-07-04
IL238326B (en) 2018-03-29
UA117000C2 (uk) 2018-06-11
IL238326A0 (en) 2015-06-30
KR20200108923A (ko) 2020-09-21
MX2015004874A (es) 2015-08-05
CN105050601A (zh) 2015-11-11
MY176599A (en) 2020-08-18
AU2013202768A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
JP6470822B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6470821B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
JP6114554B2 (ja) Ｔｏｒキナーゼ阻害剤に対する感受性についての予測的なバイオマーカーとしてのｌｋｂ１変異の同定
JP6470820B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
EP2825170B1 (en) Treatment of cancer with tor kinase inhibitors
JP7162543B2 (ja) Ｔｏｒキナーゼ阻害剤を用いた癌の治療
TW201733585A (zh) 以ｔｏｒ激酶抑制劑治療癌症
JP2015536450A (ja) ＴＯＲキナーゼ阻害活性についてのマーカーとしての、ＰＲＡＳ４０、ＧＳＫ３βまたはＰ７０Ｓ６Ｋ１のリン酸化の阻害
JP2016516671A (ja) Ｔｏｒキナーゼ阻害剤を用いたがんの治療
HK40013177A (en) Treatment of prostate cancer with tor kinase inhibitors
AU2015213397A1 (en) Treatment of cancer with TOR kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181002